Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process

Abstract

Background Nausea and vomiting are common and distressing side effects for children receiving chemotherapy. Limited evidence is available to guide antiemetic recommendations; therefore, prospective and reliable evaluation of antiemetic efficacy is needed. Smartphone apps can be used to effortlessly and precisely collect patient-reported outcomes in real time. Objective Our objective was to develop a smartphone app to monitor nausea and vomiting episodes in pediatric cancer patients aged 0 to 18 years and to test its usability and adherence to its use. Methods We used a user-centered design process and the evolutionary prototype model to develop and evaluate the app. Multidisciplinary group discussions and several rounds of patient feedback and modification were conducted. We translated the validated Pediatric Nausea Assessment Tool to assess nausea severity in children aged 4 to 18 years. The child’s own term for nausea was interactively incorporated in the nausea severity question, with response options expressed as 4 illustrative faces. Parent-reported outcomes were used for children aged 0 to 3 years. Reminders were sent using push notifications in order to ensure high response rates. Children aged 0 to 18 years who were undergoing chemotherapy were recruited from the Department of Pediatric Oncology at Copenhagen University Hospital Rigshospitalet to evaluate the app. Results The app’s most important function was to record nausea severity in children. After assistance from a researcher, children aged 4 to 18 years were able to report their symptoms in the app, and parents were able to report symptoms for their children aged 0 to 3 years. Children (n=20, aged 2.0-17.5 years) and their parents evaluated the app prospectively during a collective total of 60 chemotherapy cycles. They expressed that the app was user-friendly, intuitive, and that the time spent on data entry was fair. The response rates were on average 92%, 93%, and 80% for the day before, the first day of, and the next 3 days after chemotherapy, respectively. Researchers and clinicians were able to obtain an overview of the patient’s chemotherapy dates and responses through a secure and encrypted web-based administrative portal. Data could be downloaded for further analysis. Conclusions The user-friendly app could be used to facilitate future pediatric antiemetic trials and to refine antiemetic treatment during chemotherapy.

Using Biometric Sensor Data to Monitor Cancer Patients During Radiotherapy: Protocol for the OncoWatch Feasibility Study

“…ZiteLab ApS has developed the OncoWatch app, which collects data from the Apple HealthKit and sends it to a secure cloud server [ 20 ]. The primary investigator has access to the database.…”

Electronic Patient Reported Outcomes (ePROs) dalam Pengukuran dan Pemantauan Gejala pada Anak dengan Kanker: Studi Literatur

“…Satu dari 9 artikel menyebutkan penggunaan ePROs pada layanan rawat jalan, 16 dan satu artikel di layanan rawat inap kemoterapi. 17 Sementara tujuh artikel lainnya tidak spesifik mendeskripsikan tempat penerapan ePROs. Hal ini menunjukkan bahwa pengembangan ePROs masih didominasi oleh negara dengan penghasilan tinggi atau High Income Country (HIC).…”

“…Sementara pelaporan mandiri oleh pasien hanya dilakukan oleh anak berusia 4-18 tahun, seperti halnya target responden yang akan diikutsertakan dalam intervensi sistem RESPONSE pada artikel lainnya. 17 Proyek pengembangan aplikasi lainnya yang bernama MyPal, menargetkan responden berusia 6-17 tahun. 4 Secara garis besar, pelaporan gejala mandiri oleh pasien anak, yang langsung secara elektronik, dapat efektif digunakan pada anak usia 8-18 tahun karena pada usia tersebut pasien dianggap sudah mampu menginterpretasikan pertanyaan yang dimaksud dalam sebuah pengkajian gejala dan mampu menggunakan teknologi aplikasi atau sistem pelaporan gejala secara mandiri.…”

Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study

“…Patients aged 4 to 18 years and parents of children aged 0 to 3 years reported nausea severity and emetic episodes prospectively in a mobile app. The Pediatric Nausea Assessment Tool was incorporated into the app to evaluate nausea severity [11]. The primary outcome was complete control of acute CINV defined as no emetic episodes and no nausea 0 to 24 hours after chemotherapy administration.…”